{"id":46323,"date":"2022-07-19T16:02:01","date_gmt":"2022-07-19T14:02:01","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\/"},"modified":"2022-07-19T16:02:01","modified_gmt":"2022-07-19T14:02:01","slug":"synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\/","title":{"rendered":"SYNAPS Dx Showcases Autopsy-Confirmed Results for DISCERN Alzheimer\u2019s Test MI Biomarker, For Identifying Alzheimer\u2019s in Presence of Other Co-Morbid Pathologies"},"content":{"rendered":"
\n

ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx<\/a> (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer\u2019s disease (AD), is pleased to announce its upcoming presentation of \u201cAutopsy-Confirmed Minimally Invasive Biomarker Identifies Alzheimer’s Disease even in the Presence of Co-Morbid Pathologies\u201d at the <\/i>Alzheimer’s Association International Conference<\/a> (AAIC), July 31 \u2013 Aug. 4, 2022, in San Diego.\n<\/p>\n

<\/a><\/p>\n

\n\u201cOver 50% of people with AD have additional co-morbid pathologies of dementia, such as multi-infarct dementia, Parkinson\u2019s disease or Frontal Lobe Dementia,\u201d says Dr. Daniel Alkon, chief scientific advisor, SDx. \u201cAt the AAIC, we will present specific data evaluating the ability of the Morphometric Imaging (MI) assay in DISCERN to identify AD in people diagnosed with dementia, even in the presence of other co-morbid pathologies at autopsy.\u201d\n<\/p>\n

\nDr. Alkon further explains that DISCERN\u2122<\/a> is a diagnostic skin test comprised of three assays that assess the factors directly related to the formation of synaptic connections in the brain impacting loss of memory and cognition in people living with AD. The DISCERN AD Biomarkers also assess factors that regulate amyloid plaque and tau formation, hallmarks of AD at autopsy.\n<\/p>\n

\nDISCERN has demonstrated >95% specificity and sensitivity in identifying AD through long duration blind, autopsy-validated clinical trials with reference to the National Institutes of Health criteria that define AD at autopsy<\/a>.\n<\/p>\n

\n\u201cDISCERN<\/a> is an important breakthrough for the AD community because there are currently no FDA-approved tests that are highly sensitive and highly specific for AD in early dementia,\u201d says Frank Amato, CEO and president, SDx. \u201cWhile previously published data further validated with autopsies demonstrate both high specificity and high sensitivity, this will be the first data assessing the ability of the MI assay to accurately distinguish AD in people with comorbid dementias.\u201d\n<\/p>\n

\nAAIC attracts the world\u2019s leading basic scientists, clinical researchers, early career investigators, clinicians and the care research community to share breaking research discoveries that will lead to methods of prevention and treatment and improvements in diagnosis for AD.\n<\/p>\n

\nFor more information, visit us at booth #322 at the AAIC.\n<\/p>\n

\nAbout SYNAPS Dx<\/b>\n<\/p>\n

\nSYNAPS Dx is a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer\u2019s disease (AD). The Company offers DISCERN\u2122, the first highly accurate, minimally invasive test supporting a clinician\u2019s definitive diagnosis of AD versus other forms of dementia, even in people recently diagnosed with dementia. SYNAPS Dx\u2019s laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. Physicians and patients seeking more information can visit https:\/\/discerntest.com\/<\/a>. For more information on the Company, visit https:\/\/www.synapsdx.com\/<\/a>. Contact: info@synapsdx.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/b>
Caroline Chambers
\n
CPR Communications
\n
cchambers@cpronline.com<\/a>
201.641.1911 x 21\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer\u2019s disease (AD), is pleased to announce its upcoming presentation of \u201cAutopsy-Confirmed Minimally Invasive Biomarker Identifies Alzheimer’s Disease even in the Presence of Co-Morbid Pathologies\u201d at the Alzheimer’s Association International Conference (AAIC), July 31 … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46323","6":"format-standard","7":"category-industry"},"yoast_head":"\nSYNAPS Dx Showcases Autopsy-Confirmed Results for DISCERN Alzheimer\u2019s Test MI Biomarker, For Identifying Alzheimer\u2019s in Presence of Other Co-Morbid Pathologies - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SYNAPS Dx Showcases Autopsy-Confirmed Results for DISCERN Alzheimer\u2019s Test MI Biomarker, For Identifying Alzheimer\u2019s in Presence of Other Co-Morbid Pathologies - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer\u2019s disease (AD), is pleased to announce its upcoming presentation of \u201cAutopsy-Confirmed Minimally Invasive Biomarker Identifies Alzheimer’s Disease even in the Presence of Co-Morbid Pathologies\u201d at the Alzheimer’s Association International Conference (AAIC), July 31 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-19T14:02:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220719005059\/en\/1514662\/21\/SYNAPS_DX_LOGO_COLOR_HORIZONTAL.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"SYNAPS Dx Showcases Autopsy-Confirmed Results for DISCERN Alzheimer\u2019s Test MI Biomarker, For Identifying Alzheimer\u2019s in Presence of Other Co-Morbid Pathologies\",\"datePublished\":\"2022-07-19T14:02:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\\\/\"},\"wordCount\":480,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220719005059\\\/en\\\/1514662\\\/21\\\/SYNAPS_DX_LOGO_COLOR_HORIZONTAL.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\\\/\",\"name\":\"SYNAPS Dx Showcases Autopsy-Confirmed Results for DISCERN Alzheimer\u2019s Test MI Biomarker, For Identifying Alzheimer\u2019s in Presence of Other Co-Morbid Pathologies - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220719005059\\\/en\\\/1514662\\\/21\\\/SYNAPS_DX_LOGO_COLOR_HORIZONTAL.jpg\",\"datePublished\":\"2022-07-19T14:02:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220719005059\\\/en\\\/1514662\\\/21\\\/SYNAPS_DX_LOGO_COLOR_HORIZONTAL.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220719005059\\\/en\\\/1514662\\\/21\\\/SYNAPS_DX_LOGO_COLOR_HORIZONTAL.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SYNAPS Dx Showcases Autopsy-Confirmed Results for DISCERN Alzheimer\u2019s Test MI Biomarker, For Identifying Alzheimer\u2019s in Presence of Other Co-Morbid Pathologies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SYNAPS Dx Showcases Autopsy-Confirmed Results for DISCERN Alzheimer\u2019s Test MI Biomarker, For Identifying Alzheimer\u2019s in Presence of Other Co-Morbid Pathologies - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\/","og_locale":"en_US","og_type":"article","og_title":"SYNAPS Dx Showcases Autopsy-Confirmed Results for DISCERN Alzheimer\u2019s Test MI Biomarker, For Identifying Alzheimer\u2019s in Presence of Other Co-Morbid Pathologies - Pharma Trend","og_description":"ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer\u2019s disease (AD), is pleased to announce its upcoming presentation of \u201cAutopsy-Confirmed Minimally Invasive Biomarker Identifies Alzheimer’s Disease even in the Presence of Co-Morbid Pathologies\u201d at the Alzheimer’s Association International Conference (AAIC), July 31 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-19T14:02:01+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220719005059\/en\/1514662\/21\/SYNAPS_DX_LOGO_COLOR_HORIZONTAL.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"SYNAPS Dx Showcases Autopsy-Confirmed Results for DISCERN Alzheimer\u2019s Test MI Biomarker, For Identifying Alzheimer\u2019s in Presence of Other Co-Morbid Pathologies","datePublished":"2022-07-19T14:02:01+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\/"},"wordCount":480,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220719005059\/en\/1514662\/21\/SYNAPS_DX_LOGO_COLOR_HORIZONTAL.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\/","url":"https:\/\/pharma-trend.com\/en\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\/","name":"SYNAPS Dx Showcases Autopsy-Confirmed Results for DISCERN Alzheimer\u2019s Test MI Biomarker, For Identifying Alzheimer\u2019s in Presence of Other Co-Morbid Pathologies - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220719005059\/en\/1514662\/21\/SYNAPS_DX_LOGO_COLOR_HORIZONTAL.jpg","datePublished":"2022-07-19T14:02:01+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220719005059\/en\/1514662\/21\/SYNAPS_DX_LOGO_COLOR_HORIZONTAL.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220719005059\/en\/1514662\/21\/SYNAPS_DX_LOGO_COLOR_HORIZONTAL.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/synaps-dx-showcases-autopsy-confirmed-results-for-discern-alzheimers-test-mi-biomarker-for-identifying-alzheimers-in-presence-of-other-co-morbid-pathologies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"SYNAPS Dx Showcases Autopsy-Confirmed Results for DISCERN Alzheimer\u2019s Test MI Biomarker, For Identifying Alzheimer\u2019s in Presence of Other Co-Morbid Pathologies"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46323","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46323"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46323\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46323"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46323"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46323"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}